Article thumbnail

SERCA2a gene transfer improves electrocardiographic performance in aged mdx mice

By Jin-Hong Shin, Brian Bostick, Yongping Yue, Roger Hajjar and Dongsheng Duan
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.

Suggested articles


  1. (2008). Adeno-associated virus serotype-9 microdystrophin gene therapy ameliorates electrocardiographic abnormalities in mdx mice. Hum Gene Ther
  2. (2006). C-terminal truncated microdystrophin recruits dystrobrevin and syntrophin to the dystrophin-associated glycoprotein complex and reduces muscular dystrophy in symptomatic utrophin/ dystrophin double knock-out mice. Mol Ther
  3. (2006). Challenges and opportunities in dystrophin-deficient cardiomyopathy gene therapy. Hum Mol Genet
  4. (2010). CM: Dystrophin immunity in Duchenne’s muscular dystrophy.
  5. (2006). Cognard C: New insights in the regulation of calcium transfers by muscle dystrophin-based cytoskeleton: implications in DMD.
  6. (2009). Current understanding and management of dilated cardiomyopathy in Duchenne and Becker muscular dystrophy.
  7. D: AAV-microdystrophin therapy improves cardiac performance in aged female mdx mice. Mol Ther 2011, online publication on
  8. (2009). D: Cardiac expression of a mini-dystrophin that normalizes skeletal muscle force only partially restores heart function in aged Mdx mice. Mol Ther
  9. (2003). Decreased mAKAP, ryanodine receptor, and SERCA2a gene expression in mdx hearts. Biochem Biophys Res Commun
  10. (2008). Design of a phase 1/2 trial of intracoronary administration of AAV1/SERCA2a in patients with heart failure.
  11. (2007). DG: Intracellular calcium handling in ventricular myocytes from mdx mice.
  12. Duchenne cardiomyopathy gene therapy.
  13. (2005). Efficient in vivo gene expression by trans-splicing adeno-associated viral vectors. Nat Biotechnol
  14. (2007). Efficient whole-body transduction with trans-splicing adeno-associated viral vectors. Mol Ther
  15. (2010). Gender influences cardiac function in the mdx model of Duchenne cardiomyopathy. Muscle Nerve
  16. (2011). Gene delivery of sarcoplasmic reticulum calcium ATPase inhibits ventricular remodeling in ischemic mitral regurgitation. Circ Heart Fail 2010, 3:627-634. Shin et al.
  17. (2007). Hajjar RJ: Restoration of mechanical and energetic function in failing aortic-banded rat hearts by gene transfer of calcium cycling proteins.
  18. (2008). Hajjar RJ: Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure.
  19. (2010). Hajjar RJ: Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure. Expert Opin Biol Ther
  20. (2010). Hajjar RJ: SERCA2a gene transfer enhances eNOS expression and activity in endothelial cells. Mol Ther
  21. (2008). Hajjar RJ: The cardiac sarcoplasmic/endoplasmic reticulum calcium ATPase: a potent target for cardiovascular diseases. Nat Clin Pract Cardiovasc Med
  22. (2005). JM: Dystrophic heart failure blocked by membrane sealant poloxamer. Nature
  23. (2007). JM: Systemic Administration of Micro-dystrophin Restores Cardiac Geometry and Prevents Dobutamine-induced Cardiac Pump Failure. Mol Ther
  24. (2010). Lacampagne A: Leaky RyR2 trigger ventricular arrhythmias in Duchenne muscular dystrophy. Proc Natl Acad Sci USA
  25. (2005). Lompre AM, Huchet-Cadiou C: Effect of cyclopiazonic acid, an inhibitor of the sarcoplasmic reticulum Ca-ATPase, on skeletal muscles from normal and mdx mice. Acta Physiol Scand
  26. (2003). Microdystrophin Gene Therapy of Cardiomyopathy Restores DystrophinGlycoprotein Complex and Improves Sarcolemma Integrity in the Mdx Mouse Heart. Circulation
  27. (2011). Molkentin JD: Mitigation of muscular dystrophy in mice by SERCA overexpression in skeletal muscle.
  28. (2009). Niggli E: Pathways of abnormal stress-induced Ca2+ influx into dystrophic mdx cardiomyocytes. Cell Calcium
  29. (2010). NP: Calcium and the damage pathways in muscular dystrophy.
  30. (2011). Phenotyping cardiac gene therapy in mice. Methods Mol Biol
  31. (2008). Prevention of Dystrophin-Deficient Cardiomyopathy in Twenty-One-Month-Old Carrier Mice by Mosaic Dystrophin Expression or Complementary Dystrophin/Utrophin Expression. Circ Res
  32. (2008). QL: Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer. Proc Natl Acad Sci USA
  33. (1991). Radda GK: Total ion content of skeletal and cardiac muscle in the mdx mouse dystrophy: Ca2+ is elevated at all ages.
  34. (2005). Rafael-Fortney JA: Utrophin deficiency worsens cardiac contractile dysfunction present in dystrophin-deficient mdx mice.
  35. (1995). RC: Properties of cardiac cells from dystrophic mouse.
  36. (2003). Schwinger RH: Sarcoplasmic reticulum Ca2 +-ATPase modulates cardiac contraction and relaxation. Cardiovasc Res
  37. (2007). Systemic AAV-9 transduction in mice is influenced by animal age but not by the route of administration. Gene Ther
  38. (2009). Systemic trans-splicing AAV delivery efficiently transduces the heart of adult mdx mouse, a model for Duchenne muscular dystrophy. Hum Gene Ther
  39. (2004). Trans-splicing adenoassociated viral vector-mediated gene therapy is limited by the accumulation of spliced mRNA but not by dual vector coinfection efficiency. Hum Gene Ther
  40. (2009). Zsebo KM, Hajjar RJ: Calcium upregulation by percutaneous administration of gene therapy in cardiac disease (CUPID Trial), a first-in-human phase 1/2 clinical trial.